AI and Live Tumor Profiling Aim to Boost Cancer Therapy Success

MADISON, Wis. – April 16, 2026 – In a move that signals a significant step forward in the fight against cancer, Elephas Biosciences Corporation and the artificial intelligence firm Mithrl have announced a scientific collaboration. The partnership integrates Elephas's novel platform for analyzing live patient tumor tissue with Mithrl's autonomous AI engine, creating a powerful new tool aimed at solving one of modern oncology's most pressing challenges: predicting who will respond to immunotherapy.

Immunotherapies, which unleash a patient's own immune system to fight cancer, have revolutionized treatment but currently only benefit about one in five patients. The inability to accurately predict a patient's response beforehand leads to a difficult trial-and-error process, exposing many to costly and potentially toxic treatments with no therapeutic benefit. This new collaboration seeks to replace that uncertainty with data-driven precision.

Initial findings from the joint effort are being presented this week at the prestigious American Association for Cancer Research (AACR) Annual Meeting, showcasing how the fusion of advanced biology and agentic AI can uncover previously hidden signals of treatment response.

A New Paradigm for Predicting Treatment Success

At the heart of the collaboration is the Elephas elive™ platform, a technology designed to overcome the limitations of current predictive biomarkers. For years, clinicians have relied on static indicators like PD-L1 protein expression or tumor mutational burden to guide immunotherapy decisions. While useful, these markers provide an incomplete picture and often fail to capture the dynamic interplay within the tumor.

Elephas takes a fundamentally different approach by working with live tumor fragments extracted from standard core needle biopsies. The company has developed a proprietary hydrogel that preserves the tissue, keeping not just the cancer cells but the entire native tumor microenvironment (TME)—including crucial immune cells—viable for analysis outside the body. This ex vivo model provides a functional snapshot of the patient's unique tumor biology.

Within this living system, the elive™ platform assesses the tumor's real-time reaction to immunotherapy drugs. By measuring the release of specific proteins called cytokines, which signal immune cell activation, the platform can generate a functional profile of the tumor's inducible immune response. This method also ingeniously addresses the challenge of tumor heterogeneity—the fact that different parts of a tumor can have different characteristics—by applying sequential treatments to the same tissue fragment, ensuring a more reliable assessment from limited biopsy material.

The Power of Agentic AI in Drug Discovery

Pairing with Elephas's rich biological data is Mithrl's Scientific Decision Engine (SDE), a platform that represents the next evolution of AI in life sciences. This is not simply machine learning for data analysis; Mithrl employs 'agentic AI,' an autonomous system capable of reasoning, planning, and executing complex, multi-step scientific workflows with minimal human oversight.

The pharmaceutical industry is famously burdened by a slow and expensive R&D process, where new medicines can take over a decade and billions of dollars to reach patients, with a 90% failure rate in clinical trials. Mithrl’s SDE is designed to compress this discovery loop. The AI agent can autonomously design analytical strategies, integrate vast and disparate datasets, generate hypotheses, and test them in silico, allowing scientists to move from raw data to reproducible insights at an unprecedented speed.

"Collaborating with Elephas allows us to pair their unprecedented real-time tumor profiling from live tumor biopsies with Mithrl's SDE to unlock deep biological insights that would otherwise remain elusive or take months to surface," said Vivek Adarsh, Co-Founder and CEO of Mithrl. "I believe this combination exemplifies the future of translational research."

From Live Tissue Data to Actionable Insights

The true power of the partnership lies in this synergy. Elephas generates a torrent of complex, high-dimensional functional data that captures the nuances of a patient's immune response. Mithrl's agentic AI provides the analytical horsepower to navigate this data, identify meaningful patterns, and integrate them with external genomic and clinical datasets to discover novel and robust biomarkers of response.

"Partnering with Mithrl enables us to more fully leverage the richness of our functional profiling data and showcase the power of Agentic AI," noted Hinco Gierman, CSO of Elephas. He added that the speed at which Mithrl generates novel insights is impressive and will help "guide translational research and therapeutic development."

The collaboration's first public data, detailed in a poster at AACR 2026 titled "Multi-agent-augmented analysis of PD-1 checkpoint inhibitor response," offers a proof-of-concept. By analyzing the response to a common class of immunotherapy, the partners are demonstrating the platform's potential to generate biologically meaningful results far more efficiently than traditional methods.

Navigating the Future of Personalized Oncology

This initiative stands at the intersection of two of the most exciting trends in medicine: functional precision oncology and artificial intelligence. By moving beyond static genetic markers to a dynamic, real-time assessment of tumor behavior, the combined platform promises a more accurate method for patient stratification. The ultimate goal is to provide oncologists with an actionable test that can confidently guide treatment decisions, ensuring the right patient gets the right therapy at the right time.

For the four out of five patients who currently do not respond to a given immunotherapy, this technology could spare them from ineffective treatments and allow them to pursue more promising alternatives sooner. For drug developers, the ability to rapidly identify response signals and select more homogenous patient populations for clinical trials could significantly de-risk and accelerate the path to market for new life-saving therapies.

While the journey from a research collaboration to a widely adopted clinical tool involves significant hurdles, including extensive clinical validation and regulatory review, this partnership represents a clear and compelling vision for the future. It is a future where the complexity of cancer is met with an equally sophisticated fusion of biology and intelligence, accelerating the pace of discovery and offering new hope to patients and their families.